We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Should Growth Investors Buy this Cancer Screening Biotech Stock?
Read MoreHide Full Article
Exact Sciences (EXAS - Free Report) is the biotech firm behind the popular at-home colon cancer screening test, Cologuard. The FDA approved the test in 2014 and EXAS boasts that it “finds 92% of colon cancers and 69% of the highest-risk precancers with 87% specificity.”
The Simple Case
Cologuard’s test volume surged 80% to 1.68 million in 2019, up from 934,000 in 2018, according to the firm’s preliminary Q4 results released its January.
Colon cancer was the third leading cause of cancer deaths in 2018, according to the World Health Organization. Luckily, cancer death rates are on the decline and the U.S. rate fell 2.2% in 2017 (most recent figures). This marked the largest single-year drop ever recorded by the American Cancer Society.
The continued expansion of preventative healthcare, such as screenings, is sure to help in the fight against the second-leading cause of death worldwide.
With this in mind, EXAS shares have soared over 415% in the last three years and Cologuard commercials have become more and more common. Despite its industry-crushing run, EXAS stock is down 10% in the last six months, which might set up a solid buying opportunity.
In mid-December, Cowen analyst Doug Schenkel claimed that Exact Sciences was undervalued by 50%. This note came out roughly a month after EXAS completed its acquisition of Genomic Health, which is expected to expand its product pipeline to address other cancers.
Outlook
Our Zacks estimates call for EXAS to post fiscal 2019 revenue of $875.5 million. This would mark a roughly 92% climb from 2018’s $454 Million, which was up 71% from 2017. Peeking ahead, Exact Sciences’ 2020 sales are projected to soar another 87% to $1.63 billion.
Meanwhile, its adjusted 2020 loss is projected to come in at -$0.41. This would mark solid improvement from our -$1.61 per share estimate in 2019.
Bottom Line
EXAS is currently a Zacks Rank #3 (Hold) that is part of a highly-ranked Zacks industry that includes Moderna, Inc. (MRNA - Free Report) , Guardant Health, Inc. (GH - Free Report) , Repligen Corporation (RGEN - Free Report) , and others.
Exact Sciences is set to report its official Q4 and full-year fiscal 2019 financial results on February 11. And it certainly appears that EXAS is a biotech stock that growth-minded investors should think about buying, or at least keep an eye on.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
Should Growth Investors Buy this Cancer Screening Biotech Stock?
Exact Sciences (EXAS - Free Report) is the biotech firm behind the popular at-home colon cancer screening test, Cologuard. The FDA approved the test in 2014 and EXAS boasts that it “finds 92% of colon cancers and 69% of the highest-risk precancers with 87% specificity.”
The Simple Case
Cologuard’s test volume surged 80% to 1.68 million in 2019, up from 934,000 in 2018, according to the firm’s preliminary Q4 results released its January.
Colon cancer was the third leading cause of cancer deaths in 2018, according to the World Health Organization. Luckily, cancer death rates are on the decline and the U.S. rate fell 2.2% in 2017 (most recent figures). This marked the largest single-year drop ever recorded by the American Cancer Society.
The continued expansion of preventative healthcare, such as screenings, is sure to help in the fight against the second-leading cause of death worldwide.
With this in mind, EXAS shares have soared over 415% in the last three years and Cologuard commercials have become more and more common. Despite its industry-crushing run, EXAS stock is down 10% in the last six months, which might set up a solid buying opportunity.
In mid-December, Cowen analyst Doug Schenkel claimed that Exact Sciences was undervalued by 50%. This note came out roughly a month after EXAS completed its acquisition of Genomic Health, which is expected to expand its product pipeline to address other cancers.
Outlook
Our Zacks estimates call for EXAS to post fiscal 2019 revenue of $875.5 million. This would mark a roughly 92% climb from 2018’s $454 Million, which was up 71% from 2017. Peeking ahead, Exact Sciences’ 2020 sales are projected to soar another 87% to $1.63 billion.
Meanwhile, its adjusted 2020 loss is projected to come in at -$0.41. This would mark solid improvement from our -$1.61 per share estimate in 2019.
Bottom Line
EXAS is currently a Zacks Rank #3 (Hold) that is part of a highly-ranked Zacks industry that includes Moderna, Inc. (MRNA - Free Report) , Guardant Health, Inc. (GH - Free Report) , Repligen Corporation (RGEN - Free Report) , and others.
Exact Sciences is set to report its official Q4 and full-year fiscal 2019 financial results on February 11. And it certainly appears that EXAS is a biotech stock that growth-minded investors should think about buying, or at least keep an eye on.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>